SEARCH

SEARCH BY CITATION

References

  • 1
    The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293299.
  • 2
    Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf M, Peng G, Xiang Y, for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 8: 357370.
  • 3
    Hogg RS, Bangsberg DR, Lima VD et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med 2006; 3: e356.
  • 4
    Antiretroviral Treatment of Adult HIV Infection. Recommendations of the International AIDS Society USA Panel. JAMA 2010; 304: 321333.
  • 5
    European AIDS Clinical Society Guidelines (EACS). Guidelines for the Clinical Management and Treatment of HIV infected adults in Europe; Version 6, 2011.
  • 6
    Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (DHHS). 2012. Available at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
  • 7
    World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 rev World Health Organization. 2010.
  • 8
    Bartlett JA, Buda JJ, von Scheele B et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr 2006; 41: 323331.
  • 9
    von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Battegay M, Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167: 17821790.
  • 10
    Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 1: 712722.
  • 11
    Ndembi N, Etiebet M, Enzama R et al. Pattern of drug resistant mutations among Nigerian patients on PEPFAR NRTI – NNRTI regimens. 19th Conference on Retrovirueses and Opportunistic Infections. Seattle, 2012 [Paper 738].
  • 12
    Tang MW, Shafer RW. HIV-1 antiretroviral resistance. Scientific principles and clinical applications. Drugs 2012; 72: e1e25.
  • 13
    Peter LA, Kiser JJ, Gardner EM et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother 2011; 66: 240250.
  • 14
    von Wyl V, Yerly S, Böni J et al. Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 2012; 54: 131140.
  • 15
    Johnson VA, Calvez V, Günthard HF et al. 2011 update of the drug resistance mutations in HIV-1 [Review]. Top HIV Med 2011; 19: 156164.
  • 16
    Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811818.
  • 17
    von Wyl V, Yerly S, Böni J et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167: 17821790.
  • 18
    Hemelaar J, Gouws E, Ghys PD, Osmanov S, WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS 2011; 25: 679689.
  • 19
    Kantor R, Shafer RW, Katzenstein D, HIV-1 Non-subtype B Workgroup. The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B data. MedGenMed 2005; 7: 71.